Aurinia Pharmaceuticals (AUPH) Stock Price, Quote, News & History | Benzinga

SPY773.74 QQQ753.04 BTC/USD82,442.07−1.00%DIA506.85 GLD378.22+0.62%TLT76.74−0.52%

Aurinia Pharmaceuticals Inc (AUPH) Stock Price, Quote, News & History

AUPHNASDAQ

Trade with Public

Trade with Public

$16.01

0.322.04%

Last update: Oct 7, 4:00 PM

$16.01

0.322.04%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$16.01

Volume / Avg.

24.00 / 1.03M

Day Range

- - -

52 Wk Range

10.90 - 19.25

Market Cap

$2.13B

P/E Ratio

7.02

Dividend Yield

-

Exchange

NASDAQ

RSI

53

Short Interest

7.12%

Days to Cover

11.08

Recent Aurinia Pharmaceuticals Inc. News

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Pharmaceuticals shares rise after settling patent litigation with Teva, which can launch generic voclosporin no earlier than December 2036.

Vandana Singh

Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning

Aurinia Pharmaceuticals shares are trading higher Monday after announcing a leadership transition seen as a sign of continuity and strategy.

Henry Khederian

Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets

Aurinia Pharmaceuticals shares are trading lower Thursday afternoon after the lupus-focused drugmaker posts a blowout fourth quarter and raises expectations for continued growth in 2026.

Henry Khederian

FDA Drug Chief George Tidmarsh Resigns After Allegations Of Power Misuse

FDA drug center head George Tidmarsh resigned after accusations of misusing power to harm a former business associate. He denies wrongdoing.

Vandana Singh

US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert

U.S. stock futures were fluctuating on Friday after a mixed close on Thursday. Futures of benchmark indices were mixed in premarket.

Rishabh Mishra

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

175.24M

Investing Cash Flow (TTM)

12.84M

Financing Cash Flow (TTM)

-61.25M

Free Cash Flow (TTM)

175.07M

Capital Expenditure (TTM)

-176.00K

Net Change in Cash (TTM)

126.83M

Analyst Trends and Forecast

0

0

0

0

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

2.8

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.75B

PE Ratio (TTM)

7.02

PE Ratio (FWD)

11.45

PEG Ratio (TTM)

-

PS Ratio (TTM)

7.01

PB Ratio (TTM)

3.46

Earnings Yield % (TTM)

14.24%

Earnings Yield % (FWD)

8.73%

EV / EBITDA (TTM)

9.53

Price / EBITDA (TTM)

11.87

Price / Free Cash Flow (TTM)

12.47

Book Value / Share

$4.62

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$13.99M

Total Cash

$179.83M

Debt to Equity

0.10

Issuance of Debt (TTM)

-$13.99M

Repayment of Debt (TTM)

-$13.99M